Evergreen Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series A1
- Investors
-
5
Evergreen Therapeutics General Information
Description
Developer of biopharmaceutical drug candidates designed for the treatment of clinical indications with unmet needs. The company's technology utilizes an artificial intelligence computing platform for molecule synthesis and pharmacological prediction, enabling pharmaceutical companies to optimize biomarker screening and improve drug development efficiency.
Contact Information
Website
www.egpharm.comCorporate Office
- Room 1504, Block A, Building 1, Guangming Tianan Cloud Valley Industrial Park, Number 98
- Zhenyuan Road, Zhenmei Community, Xinhu Street, Guangming District
- Shenzhen, Guangdong 518107
- China
Corporate Office
- Room 1504, Block A, Building 1, Guangming Tianan Cloud Valley Industrial Park, Number 98
- Zhenyuan Road, Zhenmei Community, Xinhu Street, Guangming District
- Shenzhen, Guangdong 518107
- China
Evergreen Therapeutics Timeline
Evergreen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC (Series A1) | 17-Jun-2024 | Completed | Generating Revenue | |||
| 6. Early Stage VC | 20-Nov-2023 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 21-Jan-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 15-Mar-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 28-Oct-2020 | Completed | Generating Revenue | |||
| 2. Seed Round | 15-Mar-2020 | Completed | Startup | |||
| 1. University Spin-Out | 26-Aug-2019 | Completed | Startup |
Evergreen Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evergreen Therapeutics Patents
Evergreen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4772180-A1 | Dibenzazepine derivatives, pharmaceutical compositions and uses | Pending | 03-Jan-2025 | ||
| US-20260184731-A1 | Dibenzodiazepines derivatives, pharmaceutical compositions and uses | Pending | 27-Dec-2024 | ||
| EP-4238561-A1 | Use of zanamivir in preparation of drug for treating or preventing preeclampsia | Pending | 24-Nov-2020 | ||
| EP-4238561-A4 | Use of zanamivir in preparation of drug for treating or preventing preeclampsia | Pending | 24-Nov-2020 | ||
| US-20240009166-A1 | Use of zanamivir in preparation of drug for treating or preventing preeclampsia | Pending | 24-Nov-2020 | A61K31/351 |
Evergreen Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evergreen Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| SB China Venture Capital | Venture Capital | Minority | ||
| Yantai Tongju Private Equity (Investment) Fund Management | Growth/Expansion | Minority | ||
| Tiantu Capital | Venture Capital | Minority | ||
| Share Capital | Venture Capital | Minority | ||
| University of Pennsylvania | University |
Evergreen Therapeutics FAQs
-
When was Evergreen Therapeutics founded?
Evergreen Therapeutics was founded in 2019.
-
Where is Evergreen Therapeutics headquartered?
Evergreen Therapeutics is headquartered in Shenzhen, China.
-
What is the size of Evergreen Therapeutics?
Evergreen Therapeutics has 29 total employees.
-
What industry is Evergreen Therapeutics in?
Evergreen Therapeutics’s primary industry is Drug Discovery.
-
Is Evergreen Therapeutics a private or public company?
Evergreen Therapeutics is a Private company.
-
What is Evergreen Therapeutics’s current revenue?
The current revenue for Evergreen Therapeutics is .
-
How much funding has Evergreen Therapeutics raised over time?
Evergreen Therapeutics has raised $22.3M.
-
Who are Evergreen Therapeutics’s investors?
SB China Venture Capital, Yantai Tongju Private Equity (Investment) Fund Management, Tiantu Capital, Share Capital, and University of Pennsylvania have invested in Evergreen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
